Silencing of ETV6/RUNX1 abrogates PI3K/AKT/mTOR signaling and impairs reconstitution of leukemia in xenografts

Leukemia

Volumn 26, Issue 5, 2012, Pages 927-933

  Fuka, G ^a   Kantner, H P ^b   Grausenburger, R ^a   Inthal, A ^a   Bauer, E ^b   Krapf, G ^a   Kaindl, U ^a   Kauer, M ^a   Dworzak, M N ^a   Stoiber, D ^a,b   Haas, O A ^a   Panzer Grumayer R ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Childhood ALL; ETV6 RUNX1; PI3K AKT mTOR pathway; RNA interference

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 2 MORPHOLINO 8 PHENYLCHROMONE; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PREDNISOLONE SODIUM SUCCINATE; PROTEIN KINASE B; PROTEIN S6; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR RUNX1;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER RELAPSE; CELL POPULATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG SENSITIZATION; GENE SILENCING; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SCID MOUSE; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CORE BINDING FACTOR ALPHA 2 SUBUNIT; GENE SILENCING; HUMANS; MICE; PHOSPHATIDYLINOSITOL 3-KINASES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-ETS; REAL-TIME POLYMERASE CHAIN REACTION; REPRESSOR PROTEINS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRANSPLANTATION, HETEROLOGOUS;

EID: 84860750862     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.322     Document Type: Article

References (44)

1. Romana SP, Mauchauffe M, Le Coniat M, Chumakov I, Le Paslier D, Berger R et al. The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion. Blood 1995; 85: 3662-3670.
2. Moorman AV, Ensor HM, Richards SM, Chilton L, Schwab C, Kinsey SE et al. Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol 2010; 11: 429-438.
3. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet 2008; 371: 1030-1043.
4. Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grumayer R, Moricke A et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184. patients of the AIEOP-BFM ALL 2000 study. Blood 2010; 115: 3206-3214.
5. Kuster L, Grausenburger R, Fuka G, Kaindl U, Krapf G, Inthal A et al. ETV6/RUNX1-positive relapses evolve from an ancestral clone and frequently acquire deletions of genes implicated in glucocorticoid signaling. Blood 2011; 117: 2658-2667.
6. Wiemels JL, Ford AM, Van Wering ER, Postma A, Greaves M. Protracted and variable latency of acute lymphoblastic leukemia after TEL-AML1 gene fusion in utero. Blood 1999; 94: 1057-1062.
7. Konrad M, Metzler M, Panzer S, Ostreicher I, Peham M, Repp R et al. Late relapses evolve from slow-responding subclones in t(12;21)-positive acute lymphoblastic leukemia: evidence for the persistence of a preleukemic clone. Blood 2003; 101: 3635-3640.
8. Panzer-Grumayer ER, Cazzaniga G, van der Velden VH, del Giudice L, Peham M, Mann G et al. Immunogenotype changes prevail in relapses of young children with TEL-AML1-positive acute lymphoblastic leukemia and derive mainly from clonal selection. Clin Cancer Res 2005; 11: 7720-7727.
9. Mori H, Colman SM, Xiao Z, Ford AM, Healy LE, Donaldson C et al. Chromosome translocations and covert leukemic clones are generated during normal fetal development. Proc Natl Acad Sci USA 2002; 99: 8242-8247.
10. Diakos C, Krapf G, Gerner C, Inthal A, Lemberger C, Ban J et al. RNAi-mediated silencing of TEL/AML1 reveals a heat-shock protein-and survivin-dependent mechanism for survival. Blood 2007; 109: 2607-2610.
11. Steelman LS, Abrams SL, Whelan J, Bertrand FE, Ludwig DE, Basecke J et al. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia 2008; 22: 686-707.
12. Kharas MG, Okabe R, Ganis JJ, Gozo M, Khandan T, Paktinat M et al. Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice. Blood 2010; 115: 1406-1415.
13. McCubrey JA, Steelman LS, Abrams SL, Bertrand FE, Ludwig DE, Basecke J et al. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 2008; 22: 708-722.
14. Gutierrez A, Sanda T, Grebliunaite R, Carracedo A, Salmena L, Ahn Y et al. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood 2009; 114: 647-650.
15. Gandemer V, Rio AG, de Tayrac M, Sibut V, Mottier S, Ly Sunnaram B et al. Five distinct biological processes and 14 differentially expressed genes characterize TEL/AML1-positive leukemia. BMC Genomics 2007; 8: 385.
16. Andersson A, Olofsson T, Lindgren D, Nilsson Br, Ritz C, Eden P et al. Molecular signatures in childhood acute leukemia and their correlations to expression patterns in normal hematopoietic subpopulations. Proc Natl Acad Sci USA 2005; 102: 19069-19074.
17. Ross ME, Zhou X, Song G, Shurtleff SA, Girtman K, Williams WK et al. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood 2003; 102: 2951-2959.
18. Yeoh EJ, Ross ME, Shurtleff SA, Williams WK, Patel D, Mahfouz R et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002; 1: 133-143.
19. Fears S, Chakrabarti SR, Nucifora G, Rowley JD. Differential expression of TCL1 during pre-B-cell acute lymphoblastic leukemia progression. Cancer Genet Cytogenet 2002; 135: 110-119.
20. Inthal A, Krapf G, Beck D, Joas R, Kauer MO, Orel L et al. Role of the erythropoietin receptor in ETV6/RUNX1-positive acute lymphoblastic leukemia. Clin Cancer Res 2008; 14: 7196-7204.
21. Fan QW, Knight ZA, Goldenberg DD, Yu W, Mostov KE, Stokoe D et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 2006; 9: 341-349.
22. Borkhardt A, Heidenreich O. RNA interference as a potential tool in the treatment of leukaemia. Expert Opin Biol Ther 2004; 4: 1921-1929.
23. Gabert J, Beillard E, van der Velden VHJ, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of/'real-time/' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-A Europe against Cancer Program. Leukemia 2003; 17: 2318-2357.
24. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004; 5: R80.
25. Lou J, Cao W, Bernardin F, Ayyanathan K, Rauscher IF, Friedman AD. Exogenous cdk4 overcomes reduced cdk4 RNA and inhibition of G1 progression in hematopoietic cells expressing a dominant-negative CBF-a model for overcoming inhibition of proliferation by CBF oncoproteins. Oncogene 2000; 19: 2695-2703.
26. Strom DK, Nip J, Westendorf JJ, Linggi B, Lutterbach B, Downing JR et al. Expression of the AML-1 oncogene shortens the G(1) phase of the cell cycle. J Biol Chem 2000; 275: 3438-3445.
27. Bernardin F, Friedman AD. AML1 stimulates G1 to S progression via its transactivation domain. Oncogene 2002; 21: 3247-3252.
28. Ford AM, Palmi C, Bueno C, Hong D, Cardus P, Knight D et al. The TEL-AML1 leukemia fusion gene dysregulates the TGF-beta pathway in early B lineage progenitor cells. J Clin Invest 2009; 119: 826-836.
29. Krapf G, Kaindl U, Kilbey A, Fuka G, Inthal A, Joas R et al. ETV6/RUNX1 abrogates mitotic checkpoint function and targets its key player MAD2L1. Oncogene 2010; 29: 3307-3312.
30. Park IH, Bachmann R, Shirazi H, Chen J. Regulation of ribosomal S6 kinase 2 by mammalian target of rapamycin. J Biol Chem 2002; 277: 31423-31429.
31. Fine BM, Stanulla M, Schrappe M, Ho M, Viehmann S, Harbott J et al. Gene expression patterns associated with recurrent chromosomal translocations in acute lymphoblastic leukemia. Blood 2004; 103: 1043-1049.
32. Den Boer ML, van Slegtenhorst M, De Menezes RX, Cheok MH, Buijs-Gladdines JG, Peters ST et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol 2009; 10: 125-134.
33. Fuka G, Kauer M, Kofler R, Haas OA, Panzer-Grumayer R. The leukemia-specific fusion gene ETV6/RUNX1 perturbs distinct key biological functions primarily by gene repression. PLoS One 2011; 6: e26348.
34. De Vita S, Canzonetta C, Mulligan C, Delom F, Groet J, Baldo C et al. Trisomic dose of several chromosome 21 genes perturbs haematopoietic stem and progenitor cell differentiation in Down's syndrome. Oncogene 2010; 29: 6102-6114.
35. Masson K, Ronnstrand L. Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3. Cell Signal 2009; 21: 1717-1726.
36. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
37. Wotton S, Terry A, Kilbey A, Jenkins A, Herzyk P, Cameron E et al. Gene array analysis reveals a common Runx transcriptional programme controlling cell adhesion and survival. Oncogene 2008; 27: 5856-5866.
38. Frost BM, Forestier E, Gustafsson G, Nygren P, Hellebostad M, Jonsson OG et al. Translocation t(12;21) is related to in vitro cellular drug sensitivity to doxorubicin and etoposide in childhood acute lymphoblastic leukemia. Blood 2004; 104: 2452-2457.
39. Felsher DW. Oncogene addiction versus oncogene amnesia: perhaps more than just a bad habit? Cancer Res 2008; 68: 3081-3086.
40. Zaliova M, Madzo J, Cario G, Trka J. Revealing the role of TEL/AML1 for leukemic cell survival by RNAi-mediated silencing. Leukemia 2011; 25: 313-320.
41. Horton SJ, Walf-Vorderwulbecke V, Chatters SJ, Sebire NJ, de Boer J, Williams O. Acute myeloid leukemia induced by MLL-ENL is cured by oncogene ablation despite acquisition of complex genetic abnormalities. Blood 2009; 113: 4922-4929.
42. Thomas M, Gessner A, Vornlocher H-P, Hadwiger P, Greil J, Heidenreich O. Targeting MLL-AF4 with short interfering RNAs inhibits clonogenicity and engraftment of t(4;11)-positive human leukemic cells. Blood 2005; 106: 3559-3566.
43. Gessner A, Thomas M, Castro PG, Buchler L, Scholz A, Brummendorf TH et al. Leukemic fusion genes MLL/AF4 and AML1/MTG8 support leukemic self-renewal by controlling expression of the telomerase subunit TERT. Leukemia 2010; 24: 1751-1759.
44. Anderson K, Lutz C, van Delft FW, Bateman CM, Guo Y, Colman SM et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 2011; 469: 356-361.